We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document contains a synopsis of causation occurring in hip osteoarthritis.
A review of Industrial Injuries Disablement Benefit entitlement for farmers with osteoarthritis of the hip.
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
You must tell DVLA if you have arthritis and use special controls for driving - download the correct form to let them know
Information for clinicians on diagnosis and notification of Shiga toxin-producing Escherichia coli (STEC) and haemolytic uraemic syndrome (HUS).
The characteristics, symptoms, diagnosis and epidemiology of chikungunya.
Guillain-Barré syndrome is a rare neurological condition which can occur following Zika virus infection.
The epidemiology, symptoms, diagnosis and management of Nipah virus infections.
Information on the diagnosis, prevention and treatment of human parainfluenza viruses (HPIVs).
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Information to support your recovery after COVID-19.
Information for clinicians and patients.
Information and advice on rabies, the viral infection of the central nervous system which affects mammals and humans.
Advice and guidance on the health needs of migrant patients from Iran for healthcare practitioners.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.